Navigation Links
VirtualScopics, Inc. Schedules Second Quarter 2014 Financial Results Press Release, Conference Call And Webcast
Date:8/5/2014

ROCHESTER, N.Y., Aug. 5, 2014 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced it will report its second quarter and six months 2014 financial results before the market opens on Thursday, August 14, 2014.  Eric T. Converse, president and chief executive officer, and Jim Groff, acting chief financial officer, will host a conference call and webcast to discuss the company's financial results and provide a business update at 8:30 a.m. ET that morning.  Conference call, webcast and replay information is as follows:Domestic Call Dial In:  877-407-8035International Call Dial In:  201-689-8035Conference Call ID:  13587794An accompanying slide presentation to enhance managements' formal remarks, as well as a webcast of the call, can be accessed at: www.virtualscopics.com or at: http://www.investorcalendar.com/IC/CEPage.asp?ID=173036.

A replay and slide presentation will be available one hour after the conclusion of the conference call for 90 days, and can be accessed accordingly:Replay Domestic Dial In:  877-660-6853Replay International Dial In:  201-612-7415Replay Conference Call ID:  13587794Webcast and slide presentation can be accessed at:  www.virtualscopics.com or at: http://www.investorcalendar.com/IC/CEPage.asp?ID=173036.

About VirtualScopics, Inc.
VirtualScopics, Inc. (NASDAQ: VSCP) is a leading provider of clinical trial imaging solutions to accelerate drug and medical device development.  For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true exception to commonly accepted services provided by other clinical trial imaging providers.  Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, every day clinical trial imaging services.  For more information about VirtualScopics, Inc. please visit www.virtualscopics.com.

Forward-looking Statements
The statements contained in this press release that are not purely historical are forward-looking Statements within the meaning of Section 27Aof the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby.  These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure, the strategic alliance with IXICO plc  and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions.  Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations.  Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov.  These include without limitation:  the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed.  Other risks include the Company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others.  All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

For More Information, Contact:
Donna N. Stein, APR, Fellow PRSA
Managing Partner
Donna Stein & Partners
315-361-4672
Email:  dstein1@twcny.rr.com


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman
2. Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc.
3. Thoratec Schedules First Quarter Conference Call, Webcast
4. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
5. Heartware Schedules First Quarter Conference Call And Webcast
6. Ampio Pharmaceuticals Schedules 2012 Update Webcast
7. China Botanic Schedules Conference Call to Discuss Second Quarter Fiscal Year 2012 Results
8. Mylan Schedules Second Quarter 2012 Financial Results Conference Call and Live Webcast
9. Sinovac Schedules 2012 Annual Meeting of Shareholders
10. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
11. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) aired ... of 2016. The program was made possible by a Pennsylvania Department of Health ... and Human Services Administration. The broadcast, Use Your Head: Properly Managing Sport ...
(Date:12/8/2016)... Islandia, NY (PRWEB) , ... December 08, 2016 ... ... company, is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture ... published in JMIR Medical Informatics . , Results of the comparative usability ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Center has been recognized for adherence to the highest standards of trauma, ... accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among ...
(Date:12/8/2016)... ... 2016 , ... Vida Health, the digital health platform that pairs ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect ... consumers who are managing chronic conditions or simply want to improve their ...
Breaking Medicine News(10 mins):